Prostate Cancer Nuclear Medicine Diagnostics Market by Radiopharmaceutical (11C Choline, 18F DcfpyL, 18F Fluciclovine), Modality (Pet, Spect), Indication, End User - Global Forecast 2025-2032
Description
The Prostate Cancer Nuclear Medicine Diagnostics Market was valued at USD 1.15 billion in 2024 and is projected to grow to USD 1.31 billion in 2025, with a CAGR of 13.19%, reaching USD 3.12 billion by 2032.
An authoritative landscape overview describing how molecular imaging agents, detector innovations, and clinical evidence are reshaping prostate cancer diagnostic pathways
Prostate cancer diagnostics have entered a period of rapid technical maturation, driven by advances in molecular imaging agents, detector hardware, and informatics that together are reshaping clinical pathways. New radiotracers that target prostate-specific membrane antigen and other biomarkers have improved lesion detection fidelity and anatomical localization, while modern PET detector technologies and hybrid SPECT/CT workflows have increased throughput and diagnostic confidence. These developments are prompting a reassessment of referral patterns, imaging algorithms, and multidisciplinary care pathways in oncology practices and academic centers.
Alongside technical progress, regulatory approvals and payer dialogues are evolving to accommodate precision imaging as an integral part of prostate cancer management. Real-world evidence generation and prospective clinical studies are aligning to clarify the appropriate use cases for advanced nuclear imaging in initial staging, biochemical recurrence assessment, and therapy monitoring. This convergence of technology, clinical evidence, and policy considerations creates opportunities for clinical teams, manufacturers, and service providers to accelerate adoption where clinical value is demonstrable, while also emphasizing the need for robust training, quality assurance, and logistics systems to sustain safe and equitable deployment.
How converging innovations in radiotracers, imaging hardware, decentralized production and analytics are jointly redefining clinical value and operational models in prostate cancer imaging
The prostate cancer nuclear medicine landscape is experiencing transformative shifts across scientific, operational, and commercial dimensions that are redefining value creation for clinicians and patients. Molecular targeting with next-generation radiopharmaceuticals has increased lesion detectability at low disease burdens, which in turn is shifting treatment decision timing and enabling more precise focal therapies. Complementary hardware advances, including time-of-flight and digital PET, are delivering sharper images with reduced scan times and lower radiation exposure, making advanced imaging more practical in routine workflows.
Concurrently, the supply chain and manufacturing footprint for radiopharmaceuticals are evolving as production moves from centralized cyclotron models toward more distributed approaches, including generator-based systems and on-site radiochemistry capabilities. Software and analytics innovations-particularly AI-enabled lesion detection and quantitative pipelines-are helping standardize interpretation and reduce interobserver variability. Regulatory pathways are adapting to the dual needs of ensuring safety while enabling timely patient access, and reimbursement dialogues are increasingly focused on clinical utility and downstream care impact rather than diagnostic accuracy alone. Together, these shifts are not isolated; they interact to accelerate clinical integration, raise the bar for evidence generation, and reshape investment priorities across the ecosystem.
Comprehensive assessment of how 2025 tariff changes have reshaped procurement economics, supply chain resilience, and operational continuity across nuclear medicine diagnostics
The introduction of United States tariffs in 2025 has exerted multi-layered pressure on the nuclear medicine diagnostic ecosystem, altering procurement economics, supply chain strategies, and manufacturing planning. Tariff-related cost increments applied to key equipment components, isotopic precursors, and ancillary supplies have created immediate budgetary impacts for diagnostic centers and hospital systems that rely on imported goods. In response, procurement teams have initiated re-evaluations of vendor contracts, sought alternative suppliers, and accelerated requests for capital justification to mitigate the effects of higher landed costs.
Beyond direct cost implications, tariffs have affected strategic sourcing decisions and inventory management for radiopharmaceutical suppliers and imaging system manufacturers. Some organizations have accelerated localization of certain production steps and invested in regional supply redundancies to reduce vulnerability to cross-border trade fluctuations. Regulatory compliance and customs clearance processes have become more prominent considerations in logistics planning, and longer lead times for specialized components have prompted contingency planning for maintenance and spare parts. While short-term operational friction has been significant, organizations that have adopted diversified sourcing, collaborative procurement, and closer supplier partnerships have been better positioned to stabilize service continuity and protect patient access to essential diagnostic procedures.
Deep segmentation intelligence detailing how tracer chemistry, detector modality, provider setting, and clinical indication jointly determine clinical utility and operational readiness
A granular view across clinical and technical segments reveals heterogeneous adoption dynamics and operational imperatives that vary by tracer chemistry, imaging modality, service provider type, and clinical indication. Based on Radiopharmaceutical, analysis covers agents such as 11C Choline, 18F DCFPyL, 18F Fluciclovine, 68Ga PSMA, and Emerging Agents; within Emerging Agents, additional focus is placed on 18F PSMA-1007 and 64Cu PSMA. Each radiotracer presents distinct production and distribution characteristics: short-lived carbon labels require proximal cyclotron access, 18F-labeled compounds offer logistical advantages of longer half-life and centralized production, and generator-derived or longer-lived copper agents enable more flexible deployment strategies. These properties influence which sites can operationalize particular tracers and how laboratories plan capital investments in radiochemistry infrastructure.
Based on Modality, imaging pathways contrast PET and SPECT platforms; PET includes Digital PET and Time-of-Flight PET variants while SPECT encompasses Conventional SPECT and SPECT/CT configurations. Digital and TOF PET systems deliver higher sensitivity and improved quantification potential, which can materially enhance detection performance for low-volume disease, whereas SPECT and SPECT/CT remain important for centers focused on established workflows and cost containment. Based on End User, clinical adoption patterns differ across Academic Research Institutes, Diagnostic Centers, and Hospitals; academic centers often lead in early clinical validation and complex protocols, diagnostic centers prioritize throughput and operational efficiency, and hospitals integrate imaging with multidisciplinary therapeutic workflows. Based on Indication, the diagnostic value proposition shifts between Biochemical Recurrence Detection, Initial Staging, and Treatment Monitoring; detection sensitivity at low PSA levels is particularly consequential for recurrence assessment, staging requires reliable whole-body staging fidelity, and monitoring places higher emphasis on reproducibility and quantitation to inform therapeutic decisions. Understanding these segment-specific drivers is essential for aligning clinical evidence generation, reimbursement discussions, and operational investments.
Regional intelligence on adoption drivers, regulatory complexity, and supply chain realities shaping access to advanced prostate cancer imaging across global healthcare systems
Regional dynamics materially influence technology adoption, regulatory timelines, and commercial models in nuclear medicine diagnostics. In the Americas, robust clinical research networks, a concentration of tertiary care centers, and evolving reimbursement dialogues have supported early clinical integration of advanced tracers and high-end PET hardware. However, distribution challenges for isotopes and sensitivity to tariff-driven cost changes compel many providers to optimize logistics and seek supply redundancies to sustain patient access across wide geographies.
In Europe, Middle East & Africa, heterogeneous national regulatory frameworks and varying healthcare financing models create a patchwork of adoption rates; some countries lead with structured national pathways and centralized reference centers, while others face capacity and infrastructure limitations that constrain widespread uptake. Cross-border collaborations and pooled procurement initiatives have emerged as mechanisms to improve access. In the Asia-Pacific region, rapid investment in imaging infrastructure, expanding oncology services, and active local radiochemistry capabilities are accelerating adoption, though supply chain complexity and variable reimbursement frameworks require localized commercial and implementation strategies. Across all regions, clinical trial activity, regulatory harmonization efforts, and partnerships between public and private entities are pivotal determinants of how quickly and equitably new diagnostic capabilities reach patients.
Strategic competitive analysis revealing how partnerships, integrated service models, and technology differentiation are accelerating clinical integration and provider adoption
Competitive and collaborative dynamics among device manufacturers, radiopharmaceutical developers, contract manufacturing organizations, and clinical service providers are shaping the innovation landscape. Companies are focusing on integrated value propositions that combine tracer development, radiochemistry solutions, imaging hardware, and software tools to lower barriers to adoption for clinical partners. Strategic alliances and licensing arrangements are commonly used to pair imaging agents with commercial manufacturing capacity and distribution networks, while partnerships with academic centers and cooperative groups help generate the clinical evidence needed for broader clinical acceptance.
Technology vendors are differentiating on throughput, image quality, and lifecycle support, which influences procurement decisions for hospitals and diagnostic centers balancing capital expenditure and operational efficiency. Contract research organizations and specialized radiochemistry providers are expanding service offerings to support on-demand synthesis, regulatory filings, and quality assurance activities. Across the ecosystem, organizations that invest in comprehensive service models-encompassing training, technical support, and evidence generation-are more successful at reducing implementation friction and accelerating integration of novel diagnostics into multidisciplinary care pathways.
Practical strategic priorities and operational playbooks for leaders to fortify supply chains, validate clinical utility, and streamline adoption of advanced diagnostic capabilities
Industry leaders should prioritize a set of tactical and strategic actions to convert diagnostic innovation into sustained clinical and commercial value. First, invest in supply chain resilience by diversifying production channels for critical radiochemistry inputs, exploring regional manufacturing capacity, and establishing strategic inventory buffers for essential consumables. Second, align evidence generation with payer expectations by designing prospective studies and real-world assessments that demonstrate clinical utility in decision-making, downstream treatment impacts, and patient-centered outcomes.
Third, embrace modular technology strategies that allow incremental upgrades to imaging hardware and software rather than comprehensive platform replacements, thereby lowering capital barriers for providers. Fourth, develop strong go-to-clinic partnerships with academic centers and high-volume hospitals to validate protocols, create standardized operating procedures, and expedite training for technologists and physicians. Fifth, engage proactively with regulatory bodies and reimbursement stakeholders to clarify indications of use and valuation metrics. Finally, integrate digital tools such as AI-assisted interpretation and workflow automation to improve consistency, reduce time-to-result, and document value in measurable clinical endpoints that support sustained utilization.
Transparent multi-method research approach combining clinical literature synthesis, regulatory analysis, expert interviews, and operational case studies to validate practical insights
The research approach underpinning this executive summary integrated systematic review of peer-reviewed clinical literature, analysis of regulatory filings and guidance, synthesis of clinical trial registries, and structured interviews with multidisciplinary stakeholders including clinicians, radiopharmacists, imaging technologists, and procurement specialists. Source materials were triangulated across multiple evidence streams to ensure that clinical claims, operational assertions, and supply chain observations reflect corroborated information. Where appropriate, patent landscapes and manufacturing capacity signals were analyzed to understand production constraints and innovation trajectories.
Qualitative insights were validated through expert consultations to capture real-world implementation challenges and procedural nuances that are seldom visible in public documents. Operational data on imaging workflows, scanner utilization, and radiochemistry processes were aggregated from institutional case studies and technical white papers, then normalized to highlight common barriers and successful mitigation strategies. Throughout the research process, emphasis was placed on transparency of methods, reproducibility of analytic steps, and clear documentation of assumptions to support readers in applying findings within their institutional contexts.
Concise synthesis of clinical promise, implementation barriers, and multi-stakeholder steps required to translate diagnostic innovation into improved patient care
Advanced nuclear medicine diagnostics for prostate cancer present a meaningful opportunity to improve staging accuracy, guide personalized treatment decisions, and monitor therapeutic response with greater precision than many traditional imaging approaches. Real-world implementation will depend on coordinated investments in radiochemistry capabilities, detector hardware, and credentialing of multidisciplinary teams to ensure high-quality, reproducible results. Policy and reimbursement dialogues will continue to play a decisive role in determining how rapidly these tools are assimilated into standard care pathways, and evidence generation focused on patient outcomes and care efficiency will remain a critical enabler.
Clinicians, health system leaders, manufacturers, and payers each have a role in addressing practical barriers such as supply chain fragility, workforce training needs, and heterogeneous regulatory frameworks. Organizations that align clinical validation with operational readiness and payer engagement can improve the likelihood that technical advances translate into measurable patient benefit. Continued collaboration across public and private stakeholders will be essential to scale access equitably and sustainably.
Please Note: PDF & Excel + Online Access - 1 Year
An authoritative landscape overview describing how molecular imaging agents, detector innovations, and clinical evidence are reshaping prostate cancer diagnostic pathways
Prostate cancer diagnostics have entered a period of rapid technical maturation, driven by advances in molecular imaging agents, detector hardware, and informatics that together are reshaping clinical pathways. New radiotracers that target prostate-specific membrane antigen and other biomarkers have improved lesion detection fidelity and anatomical localization, while modern PET detector technologies and hybrid SPECT/CT workflows have increased throughput and diagnostic confidence. These developments are prompting a reassessment of referral patterns, imaging algorithms, and multidisciplinary care pathways in oncology practices and academic centers.
Alongside technical progress, regulatory approvals and payer dialogues are evolving to accommodate precision imaging as an integral part of prostate cancer management. Real-world evidence generation and prospective clinical studies are aligning to clarify the appropriate use cases for advanced nuclear imaging in initial staging, biochemical recurrence assessment, and therapy monitoring. This convergence of technology, clinical evidence, and policy considerations creates opportunities for clinical teams, manufacturers, and service providers to accelerate adoption where clinical value is demonstrable, while also emphasizing the need for robust training, quality assurance, and logistics systems to sustain safe and equitable deployment.
How converging innovations in radiotracers, imaging hardware, decentralized production and analytics are jointly redefining clinical value and operational models in prostate cancer imaging
The prostate cancer nuclear medicine landscape is experiencing transformative shifts across scientific, operational, and commercial dimensions that are redefining value creation for clinicians and patients. Molecular targeting with next-generation radiopharmaceuticals has increased lesion detectability at low disease burdens, which in turn is shifting treatment decision timing and enabling more precise focal therapies. Complementary hardware advances, including time-of-flight and digital PET, are delivering sharper images with reduced scan times and lower radiation exposure, making advanced imaging more practical in routine workflows.
Concurrently, the supply chain and manufacturing footprint for radiopharmaceuticals are evolving as production moves from centralized cyclotron models toward more distributed approaches, including generator-based systems and on-site radiochemistry capabilities. Software and analytics innovations-particularly AI-enabled lesion detection and quantitative pipelines-are helping standardize interpretation and reduce interobserver variability. Regulatory pathways are adapting to the dual needs of ensuring safety while enabling timely patient access, and reimbursement dialogues are increasingly focused on clinical utility and downstream care impact rather than diagnostic accuracy alone. Together, these shifts are not isolated; they interact to accelerate clinical integration, raise the bar for evidence generation, and reshape investment priorities across the ecosystem.
Comprehensive assessment of how 2025 tariff changes have reshaped procurement economics, supply chain resilience, and operational continuity across nuclear medicine diagnostics
The introduction of United States tariffs in 2025 has exerted multi-layered pressure on the nuclear medicine diagnostic ecosystem, altering procurement economics, supply chain strategies, and manufacturing planning. Tariff-related cost increments applied to key equipment components, isotopic precursors, and ancillary supplies have created immediate budgetary impacts for diagnostic centers and hospital systems that rely on imported goods. In response, procurement teams have initiated re-evaluations of vendor contracts, sought alternative suppliers, and accelerated requests for capital justification to mitigate the effects of higher landed costs.
Beyond direct cost implications, tariffs have affected strategic sourcing decisions and inventory management for radiopharmaceutical suppliers and imaging system manufacturers. Some organizations have accelerated localization of certain production steps and invested in regional supply redundancies to reduce vulnerability to cross-border trade fluctuations. Regulatory compliance and customs clearance processes have become more prominent considerations in logistics planning, and longer lead times for specialized components have prompted contingency planning for maintenance and spare parts. While short-term operational friction has been significant, organizations that have adopted diversified sourcing, collaborative procurement, and closer supplier partnerships have been better positioned to stabilize service continuity and protect patient access to essential diagnostic procedures.
Deep segmentation intelligence detailing how tracer chemistry, detector modality, provider setting, and clinical indication jointly determine clinical utility and operational readiness
A granular view across clinical and technical segments reveals heterogeneous adoption dynamics and operational imperatives that vary by tracer chemistry, imaging modality, service provider type, and clinical indication. Based on Radiopharmaceutical, analysis covers agents such as 11C Choline, 18F DCFPyL, 18F Fluciclovine, 68Ga PSMA, and Emerging Agents; within Emerging Agents, additional focus is placed on 18F PSMA-1007 and 64Cu PSMA. Each radiotracer presents distinct production and distribution characteristics: short-lived carbon labels require proximal cyclotron access, 18F-labeled compounds offer logistical advantages of longer half-life and centralized production, and generator-derived or longer-lived copper agents enable more flexible deployment strategies. These properties influence which sites can operationalize particular tracers and how laboratories plan capital investments in radiochemistry infrastructure.
Based on Modality, imaging pathways contrast PET and SPECT platforms; PET includes Digital PET and Time-of-Flight PET variants while SPECT encompasses Conventional SPECT and SPECT/CT configurations. Digital and TOF PET systems deliver higher sensitivity and improved quantification potential, which can materially enhance detection performance for low-volume disease, whereas SPECT and SPECT/CT remain important for centers focused on established workflows and cost containment. Based on End User, clinical adoption patterns differ across Academic Research Institutes, Diagnostic Centers, and Hospitals; academic centers often lead in early clinical validation and complex protocols, diagnostic centers prioritize throughput and operational efficiency, and hospitals integrate imaging with multidisciplinary therapeutic workflows. Based on Indication, the diagnostic value proposition shifts between Biochemical Recurrence Detection, Initial Staging, and Treatment Monitoring; detection sensitivity at low PSA levels is particularly consequential for recurrence assessment, staging requires reliable whole-body staging fidelity, and monitoring places higher emphasis on reproducibility and quantitation to inform therapeutic decisions. Understanding these segment-specific drivers is essential for aligning clinical evidence generation, reimbursement discussions, and operational investments.
Regional intelligence on adoption drivers, regulatory complexity, and supply chain realities shaping access to advanced prostate cancer imaging across global healthcare systems
Regional dynamics materially influence technology adoption, regulatory timelines, and commercial models in nuclear medicine diagnostics. In the Americas, robust clinical research networks, a concentration of tertiary care centers, and evolving reimbursement dialogues have supported early clinical integration of advanced tracers and high-end PET hardware. However, distribution challenges for isotopes and sensitivity to tariff-driven cost changes compel many providers to optimize logistics and seek supply redundancies to sustain patient access across wide geographies.
In Europe, Middle East & Africa, heterogeneous national regulatory frameworks and varying healthcare financing models create a patchwork of adoption rates; some countries lead with structured national pathways and centralized reference centers, while others face capacity and infrastructure limitations that constrain widespread uptake. Cross-border collaborations and pooled procurement initiatives have emerged as mechanisms to improve access. In the Asia-Pacific region, rapid investment in imaging infrastructure, expanding oncology services, and active local radiochemistry capabilities are accelerating adoption, though supply chain complexity and variable reimbursement frameworks require localized commercial and implementation strategies. Across all regions, clinical trial activity, regulatory harmonization efforts, and partnerships between public and private entities are pivotal determinants of how quickly and equitably new diagnostic capabilities reach patients.
Strategic competitive analysis revealing how partnerships, integrated service models, and technology differentiation are accelerating clinical integration and provider adoption
Competitive and collaborative dynamics among device manufacturers, radiopharmaceutical developers, contract manufacturing organizations, and clinical service providers are shaping the innovation landscape. Companies are focusing on integrated value propositions that combine tracer development, radiochemistry solutions, imaging hardware, and software tools to lower barriers to adoption for clinical partners. Strategic alliances and licensing arrangements are commonly used to pair imaging agents with commercial manufacturing capacity and distribution networks, while partnerships with academic centers and cooperative groups help generate the clinical evidence needed for broader clinical acceptance.
Technology vendors are differentiating on throughput, image quality, and lifecycle support, which influences procurement decisions for hospitals and diagnostic centers balancing capital expenditure and operational efficiency. Contract research organizations and specialized radiochemistry providers are expanding service offerings to support on-demand synthesis, regulatory filings, and quality assurance activities. Across the ecosystem, organizations that invest in comprehensive service models-encompassing training, technical support, and evidence generation-are more successful at reducing implementation friction and accelerating integration of novel diagnostics into multidisciplinary care pathways.
Practical strategic priorities and operational playbooks for leaders to fortify supply chains, validate clinical utility, and streamline adoption of advanced diagnostic capabilities
Industry leaders should prioritize a set of tactical and strategic actions to convert diagnostic innovation into sustained clinical and commercial value. First, invest in supply chain resilience by diversifying production channels for critical radiochemistry inputs, exploring regional manufacturing capacity, and establishing strategic inventory buffers for essential consumables. Second, align evidence generation with payer expectations by designing prospective studies and real-world assessments that demonstrate clinical utility in decision-making, downstream treatment impacts, and patient-centered outcomes.
Third, embrace modular technology strategies that allow incremental upgrades to imaging hardware and software rather than comprehensive platform replacements, thereby lowering capital barriers for providers. Fourth, develop strong go-to-clinic partnerships with academic centers and high-volume hospitals to validate protocols, create standardized operating procedures, and expedite training for technologists and physicians. Fifth, engage proactively with regulatory bodies and reimbursement stakeholders to clarify indications of use and valuation metrics. Finally, integrate digital tools such as AI-assisted interpretation and workflow automation to improve consistency, reduce time-to-result, and document value in measurable clinical endpoints that support sustained utilization.
Transparent multi-method research approach combining clinical literature synthesis, regulatory analysis, expert interviews, and operational case studies to validate practical insights
The research approach underpinning this executive summary integrated systematic review of peer-reviewed clinical literature, analysis of regulatory filings and guidance, synthesis of clinical trial registries, and structured interviews with multidisciplinary stakeholders including clinicians, radiopharmacists, imaging technologists, and procurement specialists. Source materials were triangulated across multiple evidence streams to ensure that clinical claims, operational assertions, and supply chain observations reflect corroborated information. Where appropriate, patent landscapes and manufacturing capacity signals were analyzed to understand production constraints and innovation trajectories.
Qualitative insights were validated through expert consultations to capture real-world implementation challenges and procedural nuances that are seldom visible in public documents. Operational data on imaging workflows, scanner utilization, and radiochemistry processes were aggregated from institutional case studies and technical white papers, then normalized to highlight common barriers and successful mitigation strategies. Throughout the research process, emphasis was placed on transparency of methods, reproducibility of analytic steps, and clear documentation of assumptions to support readers in applying findings within their institutional contexts.
Concise synthesis of clinical promise, implementation barriers, and multi-stakeholder steps required to translate diagnostic innovation into improved patient care
Advanced nuclear medicine diagnostics for prostate cancer present a meaningful opportunity to improve staging accuracy, guide personalized treatment decisions, and monitor therapeutic response with greater precision than many traditional imaging approaches. Real-world implementation will depend on coordinated investments in radiochemistry capabilities, detector hardware, and credentialing of multidisciplinary teams to ensure high-quality, reproducible results. Policy and reimbursement dialogues will continue to play a decisive role in determining how rapidly these tools are assimilated into standard care pathways, and evidence generation focused on patient outcomes and care efficiency will remain a critical enabler.
Clinicians, health system leaders, manufacturers, and payers each have a role in addressing practical barriers such as supply chain fragility, workforce training needs, and heterogeneous regulatory frameworks. Organizations that align clinical validation with operational readiness and payer engagement can improve the likelihood that technical advances translate into measurable patient benefit. Continued collaboration across public and private stakeholders will be essential to scale access equitably and sustainably.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
191 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of PSMA-targeted PET imaging in early detection and staging of recurrent prostate cancer
- 5.2. Advances in radiolabeled small molecule therapeutics improving targeted radionuclide therapy outcomes in mCRPC
- 5.3. Deployment of next generation digital PET/CT scanners enhancing image resolution and quantitative accuracy in prostate cancer diagnostics
- 5.4. Regulatory approval and commercialization of novel radionuclide conjugates targeting PSMA for theranostic applications in prostate cancer patients
- 5.5. Growth of hybrid PET/MRI systems to reduce radiation exposure while improving soft tissue characterization in prostate imaging
- 5.6. Emergence of artificial intelligence algorithms for automated interpretation and prognostic risk stratification in prostate cancer nuclear scans
- 5.7. Increasing adoption of personalized dosimetry software for optimizing safety and efficacy of lutetium-177 radioligand therapy in clinical practice
- 5.8. Collaborations between academic institutions and pharma companies accelerating clinical trials of novel alpha-emitting PSMA therapies in prostate cancer management
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Prostate Cancer Nuclear Medicine Diagnostics Market, by Radiopharmaceutical
- 8.1. 11C Choline
- 8.2. 18F DcfpyL
- 8.3. 18F Fluciclovine
- 8.4. 68Ga Psma
- 8.5. Emerging Agents
- 8.5.1. 18F Psma 1007
- 8.5.2. 64Cu Psma
- 9. Prostate Cancer Nuclear Medicine Diagnostics Market, by Modality
- 9.1. Pet
- 9.1.1. Digital Pet
- 9.1.2. Time Of Flight Pet
- 9.2. Spect
- 9.2.1. Conventional Spect
- 9.2.2. Spect Ct
- 10. Prostate Cancer Nuclear Medicine Diagnostics Market, by Indication
- 10.1. Biochemical Recurrence Detection
- 10.2. Initial Staging
- 10.3. Treatment Monitoring
- 11. Prostate Cancer Nuclear Medicine Diagnostics Market, by End User
- 11.1. Academic Research Institute
- 11.2. Diagnostic Center
- 11.3. Hospital
- 12. Prostate Cancer Nuclear Medicine Diagnostics Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Prostate Cancer Nuclear Medicine Diagnostics Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Prostate Cancer Nuclear Medicine Diagnostics Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. GE HealthCare Technologies Inc.
- 15.3.2. Siemens Healthineers AG
- 15.3.3. Koninklijke Philips N.V.
- 15.3.4. Cardinal Health, Inc.
- 15.3.5. Bayer AG
- 15.3.6. Lantheus Holdings, Inc.
- 15.3.7. Bracco Imaging S.p.A.
- 15.3.8. Telix Pharmaceuticals Limited
- 15.3.9. Eckert & Ziegler Strahlen- und Medizintechnik AG
- 15.3.10. Isotope Technologies Munich SE
- 15.3.11. Novartis AG
- 15.3.12. Curium Pharma
- 15.3.13. Blue Earth Diagnostics Inc.
- 15.3.14. NCM‑USA LLC
- 15.3.15. Jubilant Radiopharma
- 15.3.16. ABX Advanced Biochemical Compounds GmbH
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
